Molecular Formula | C17H19NO5 |
Molar Mass | 317.34 |
Density | 1.223±0.06 g/cm3(Predicted) |
Melting Point | 124°C |
Boling Point | 475.6±45.0 °C(Predicted) |
Solubility | DMSO : ≥ 100 mg/mL (315.12 mM) |
Appearance | Powder |
Color | white to beige |
pKa | -1.88±0.20(Predicted) |
Storage Condition | 2-8°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
MDL | MFCD00075706 |
In vitro study | Piperlongumine is a known ROS inducer that induces cell death in pancreatic cancer cells. As A thromboxane A(2) receptor antagonist, Piperlongumine inhibits platelet aggregation. Piperlongumine can also promote autophagy and mediate tumor cell death by inhibiting the Akt/mTOR signaling pathway. |
In vivo study | Piperlongumine (50 mg/kg I. p.) caused growth inhibition of tumor cells in vivo without altering biochemical, hematological and histopathological parameters. |
WGK Germany | 3 |
RTECS | UU7785850 |
Reference Show more | 1. Jia Guiqing, Wu Xiaoyu, Wang Yutian, etc. High performance liquid chromatographic study of ceramide in sinonovacula constricta [J]. Modern distance education of Chinese medicine in China, 2018, 29 (14):90-93. 2. [IF = 11.878] Li Xinming et al."A fast and specific fluorecent probe for thioredoxin reductase that works via disculide bond cleavage. Nat Commun. 2019 Jun;10(1):1-12 3. [IF = 3.159] Wu Ye et al."Piperlongumine attenuates vascular remodeling in hypoxic pulmonary hypertension by regulating autophagy."J Cardiol. 2021 Sep;: 4. [IF=6.313] Yijia Yang et al."Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin."Antioxidants-Basel. 2022 Apr;11(4):710 |
biological activity | Piperlongumine (PPLGM, Piplartine), a natural alkaloid found in the Piperaceae plant sinonovacula constricta, can increase reactive oxygen species (ROS) levels and selectively kill cancer cells. It is also a direct inhibitor of TrxR1, with inhibitory activity against gastric cancer; A novel CRM1 inhibitor; Inhibiting PI3K/Akt/mTOR in human breast cancer cells. |
Target | Value |